ATTORNEY ADVERTISING - THE LAW OFFICE OF HAKIMI & SHAHRIARI
The Law Office of Hakimi & Shahriari
7080 Hollywood Blvd., Suite 804
Los Angeles, California 90028
Toll-Free: (888) 635 - 2250
Fax: (213) 402 - 2170
(888) 635 - 2250
Nothing on this site should be taken as legal advice for any individual case or situation. Every claim and potential legal claim must be viewed on its own merits. The information on this website is for general information purposes only. It is not intended to create, and receipt or viewing of this information does not constitute, an attorney-client relationship. Every situation and every client’s legal matter is different and this website is merely meant to provide information to the public. Nor does this website create an attorney-client relationship – such a relationship has not been formed unless a signed fee agreement has been made. If you want legal advice or want to know if you have suffered a legal wrong contact the attorneys at The Law Office of Hakimi & Shahriari at (888) 635 - 2250.
Plaintiffs from all over the country are claiming that Xarelto manufacturers failed to provide adequate labeling and failed disclose warnings about the dangerous and potentially life-threatening side effects from use of the medication; they are also alleged to have failed to properly test the drug for safety before releasing it to consumers. You may be one of the many patients entitled to compensation from the drug manufacturers through a legal claim. If you or a loved one has suffered from severe bleeding after using Xarelto, or if you believe you or a loved one has suffered from a Xarelto-related health issue, please contact our firm immediately for a free consultation.
About the Health Risks of Xarelto
Xarelto (rivaroxaban), a commonly prescribed blood-thinner approved by U.S. Food and Drug Administration (FDA), is used to block the activity of certain clotting substances in the blood. The medication works by inhibiting Factor Xa (FXa), an enzyme needed to clot the blood, thereby decreasing the risk of blood clots. It is used to reduce the risk of stroke and to prevent a specific type of blood clot referred to as deep vein thrombosis (DVT), as well as in pulmonary embolism (PE), characterized by blood clots in the lungs. Xarelto is also used in people with atrial fibrillation, a heart rhythm disorder, to lower the risk of stroke caused by a blood clot.
Although Xarelto is a widely used anticoagulant in the United States, the pharmaceutical companies that manufacture Xarelto have allegedly failed to provide warnings to patients and medical care professionals regarding the potentially irreversible and uncontrollable internal bleeding caused by the popular drug. An estimated 18,600 lawsuits against the manufacturers of Xarelto, Janssen Pharmaceuticals (subsidiary of Johnson & Johnson) and Bayer AG, have alleged that they failed to provide warnings to patients and medical care professionals regarding the life-threatening injuries that may result from use of the medication.
Marketers of Xarelto have characterized this drug as being a cut above other blood-thinning drugs without disclosing the dangerous risks and serious side effects associated with the use of this medication. While most other anticoagulants have a readily available antidote for episodes of excessive bleeding, such as Vitamin K injections to encourage blood-clotting, Xarelto does not. There is no foreseeable cure to reversing the blood loss caused by the drug, except possibly by emergency dialysis, which may not be sufficient.